New Drug Evaluations
The Committee reviewed the following new drugs.

A. Bexsero® (meningococcal group B vaccine, suspension for intramuscular injection) Novartis
B. Duopa™ (carbidopa and levodopa enteral suspension) AbbVie
C. Farydak® (panobinostat capsules) Novartis
D. Ibrance® (palbociclib capsules) Pfizer Labs
E. Lenvima™ (lenvatinib capsules) Eisai, Inc.
F. Natpara® (parathyroid hormone subcutaneous injection) NPS Pharma/Shire
G. Saxenda® (liraglutide injection) NovoNordisk
H. Signifor® LAR (pasireotide for injectable suspension, for intramuscular use) Novartis
I. Soolantra® (ivermectin cream, 1% – Gladerma)
J. Toujeo® (insulin glargine injection U-300) Sanofi
K. Zarxio™ (filgrastim-sndz injection for subcutaneous or intravenous use) Sandoz

New Indications for Existing Products
The Committee reviewed the following new indications for existing products: See product inserts for specific wording.

A. Astepro® (azelastine 0.1% nasal spray) Meda - Revised age indication for the relief of the symptoms of seasonal allergic rhinitis (SAR) in patients > 2 years of age and perennial allergic rhinitis (PAR) in patients > 6 months of age. Previously, Astepro 0.1% was indicated for the relief of symptoms of SAR and PAR in patients > 6 years of age.
B. Banzel® (rufinamide oral solution) Eisai - Revised age indication for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients > 1 year of age and in adults. Previously, Banzel was indicated for use as adjunctive treatment of seizures associated with LGS in adults and children > 4 years of age.
C. Banzel® (rufinamide tablets) Eisai - Revised age indication for adjunctive treatment of seizures associated with LGS in pediatric patients > 1 year of age and in adults.
D. Dymista® (azelastine hydrochloride and fluticasone propionate nasal spray) Meda - Revised age indication for the relief of symptoms of seasonal allergic rhinitis (SAR) in patients > 6 years of age who require treatment with both components for symptomatic relief. Previously, Dymista was indicated for adults and children > 12 years of age.
E. Flonase® (fluticasone propionate 50 mcg nasal spray) GlaxoSmithKline - Revised indication for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged > 4 years. Previously, Flonase was indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients > 4 years.

H. **Opdivo® (nivolumab injection) Bristol Myers Squibb** - New indication for the treatment of patients with metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.

I. **Revlimid® (lenalidomide capsules) Celgene** - Revised indication for use in combination with dexamethasone to treat patients with multiple myeloma (MM). Previously, Revlimid was only indicated for use in combination with dexamethasone for patients with MM who have received at least one prior therapy.


### New Clinical Line Extensions
The Committee reviewed the following new clinical line extensions.

A. **Dutrebis™ (lamivudine 150 mg and raltegravir 300 mg tablets) Merck**  
B. **Evekeo™ (amphetamine sulfate tablets) Arbor Pharmaceuticals**  
C. **Evotaz™ (cobicistat 150 mg and atazanavir 300 mg tablets) Bristol-Myers Squibb**  
D. **Glyxambi® (empagliflozin/ linagliptin tablets) Boehringer Ingelheim/Lilly**  
E. **Pazeo™ (olopatadine hydrochloride 0.7% ophthalmic solution) Alcon**  
F. **Prestalia® (perindopril arginine and amlodipine tablets) Symplmed Pharmaceuticals**  
G. **Prezcobix™ (darunavir 800 mg and cobicistat 150 mg tablets) Janssen**  
H. **Zohydro® ER (hydrocodone extended-release capsules) [with BeadTek™] Zogenix**

All trademarks are the property of their respective owners.